NovoCure (NVCR) Net Income towards Common Stockholders (2014 - 2026)
NovoCure (NVCR) posted Net Income towards Common Stockholders of -$15.7 million for Q2 2026, up 77.99% sequentially from -$71.1 million in Q1 2026, and up 60.99% YoY from -$9.7 million in Q2 2025.
NovoCure (NVCR) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
NovoCure has reported Net Income towards Common Stockholders for 13 years, with the latest figure at -$15.7 million in Q2 2026.
- Quarterly Net Income towards Common Stockholders rose 60.99% year-over-year to -$15.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$148.6 million (up 13.09% YoY) and the FY2025 annual result came in at -$136.2 million, up 19.21% from the prior year.
- Net Income towards Common Stockholders improved to -$15.7 million in Q2 2026 per NVCR's latest filing, from -$71.1 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$4.6 million in Q1 2022 and troughed at -$71.1 million in Q1 2026.
- A 5-year average of -$38.4 million and a median of -$37.3 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders slumped 1041.83% in 2023, then surged 62.84% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$37.3 million in 2022, then fell by 26.21% to -$47.1 million in 2023, then plunged by 40.02% to -$65.9 million in 2024, then soared by 62.84% to -$24.5 million in 2025, then surged by 36.09% to -$15.7 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$15.7 million, -$71.1 million, and -$24.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 201.00 Mn |
| 10 | NovoCure | 2.05 Bn | 1.61 Bn | 142.48 Mn | -15.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.66 Mn |
| Mar 31, 2026 | -71.14 Mn |
| Dec 31, 2025 | -24.50 Mn |
| Sep 30, 2025 | -37.27 Mn |
| Jun 30, 2025 | -40.14 Mn |
| Mar 31, 2025 | -34.32 Mn |
| Dec 31, 2024 | -65.92 Mn |
| Sep 30, 2024 | -30.57 Mn |
| Jun 30, 2024 | -33.38 Mn |
| Mar 31, 2024 | -38.76 Mn |
| Dec 31, 2023 | -47.08 Mn |
| Sep 30, 2023 | -49.49 Mn |
| Jun 30, 2023 | -57.42 Mn |
| Mar 31, 2023 | -53.06 Mn |
| Dec 31, 2022 | -37.30 Mn |
| Sep 30, 2022 | -26.58 Mn |
| Jun 30, 2022 | -24.01 Mn |
| Mar 31, 2022 | -4.65 Mn |
| Dec 31, 2021 | -26.46 Mn |
| Sep 30, 2021 | -13.12 Mn |